Trial Profile
A retrospective study of Pembrolizumab in Asian population with Head and Neck Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Nasopharyngeal cancer; Oropharyngeal cancer
- Focus Therapeutic Use
- 08 Mar 2018 New trial record